COPD
Conditions
Interventions
Double-drug trial group:Tiotropium bromide odardarol and indardarol maleate were used since admission
Single drug group:Tiotropium bromide was used since admission
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: (1) aged 18-79 years; (2) in accordance with the Chinese medical association respiratory neurology, chronic obstructive pulmonary disease committee for the guidance of diagnosis and treatment of chronic obstructive pulmonary disease (2013 revision) "set of diagnostic criteria, group C or D in lung function class for III - IV namely; (3) receive inhalation therapy; (4) informed consent, and signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) allergy to tiotropium bromide and odardarol/indardarol maleate or any inhaled components of inhalants; (2) patients with bronchial lung cancer, dilatation, interstitial lung disease or other diseases are not suitable for inhalation therapy; (3) other systemic diseases, including heart, liver, kidney, hematopoietic, nervous system diseases, glaucoma, severe prostatic hyperplasia; (4) doctors consider it inappropriate to take bronchodilators; (5) intraoperative lobectomy changes; (6) cannot tolerate one-lung ventilation; (7) when the woman is pregnant or breast-fed; (8) the patient is accompanied by other malignant tumors; (9) anticholinergic drugs were used in the first 4 weeks of the study, and has a history of acute episodes or antibiotics were used; has received systemic glucocorticoid therapy in the past two months; (10) With heart, liver, kidney or endocrine diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FEV1;FEV1%;MMEF; | — |
Countries
China
Contacts
Public ContactChang Chen
Shanghai Pulmonary Hospital
Outcome results
None listed